Press

2025-04-08

Kancera reports Last Patient Last Visit in the KANDOVA study

Kancera AB (publ) reports that the last patient has completed the last visit in the ongoing phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer.

Read More
2025-03-14

Kancera changes Certified Adviser to Redeye AB

Kancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.

Read More
2025-03-07

Kancera announces intention to change company name to Novakand Pharma

Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases.

Read More
2025-03-07

Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145

Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...

Read More
2025-02-21

Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...

Read More
2024-11-15

Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the third quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 10,2 million (SEK 9,2 million). Operating loss for the quarter amounted to...

Read More
2024-11-12

Kancera focuses on cardiovascular diseases

Development resources are focused on cardiovascular diseases, initially with focus on treatment of STEMI based on the positive phase IIa results in the FRACTAL-study. Extensive market access research concerning the preliminary product positioning in STEMI verifies that the opportunities...

Read More
2024-11-01

Kancera appoints Robert Edfors as Chief Medical Officer

Kancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine, has up until now been the company’s Chief Scientific...

Read More
2024-08-23

Kancera gives an operational update concerning its clinical development program

In connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that: the phase IIa part in the KANDOVA study has been initiated...

Read More
2024-08-23

Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...

Read More